Stevanato Group (NYSE:STVN) Price Target Raised to $26.00 at Bank of America

Stevanato Group (NYSE:STVN) had its price objective raised by Bank of America from $24.00 to $26.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on STVN. Wolfe Research started coverage on Stevanato Group in a research note on Friday. They issued an “outperform” rating and a $28.00 target price on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Stevanato Group presently has a consensus rating of “Moderate Buy” and a consensus target price of €28.60 ($30.11).

Stevanato Group Trading Up 3.7 %

Stevanato Group stock opened at €23.31 ($24.54) on Friday. Stevanato Group has a 1 year low of €16.56 ($17.43) and a 1 year high of €34.73 ($36.56). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The business has a 50 day moving average of €19.67 and a 200-day moving average of €19.67.

Stevanato Group (NYSE:STVN) last issued its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). The business had revenue of €277.90 million for the quarter, compared to the consensus estimate of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company’s revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 EPS. On average, analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

Hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Stevanato Group during the 3rd quarter valued at about $84,000. Raymond James Trust N.A. increased its stake in shares of Stevanato Group by 18.7% during the second quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after buying an additional 1,613 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in shares of Stevanato Group by 59.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock valued at $219,000 after acquiring an additional 4,441 shares in the last quarter. Hardy Reed LLC raised its holdings in shares of Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after acquiring an additional 840 shares in the last quarter. Finally, Lindenwold Advisors INC lifted its stake in Stevanato Group by 13.5% in the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after acquiring an additional 1,415 shares during the period.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.